Association between cerebrovasoreactivity and stroke in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy.
acetazolamide
cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
cerebrovasoreactivity
single-photon emission computed tomography
stroke
Journal
Frontiers in neurology
ISSN: 1664-2295
Titre abrégé: Front Neurol
Pays: Switzerland
ID NLM: 101546899
Informations de publication
Date de publication:
2022
2022
Historique:
received:
02
11
2022
accepted:
16
12
2022
entrez:
26
1
2023
pubmed:
27
1
2023
medline:
27
1
2023
Statut:
epublish
Résumé
Impaired cerebrovasoreactivity is thought to play an important role in the pathophysiology of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). We aimed to clarify the association between cerebrovascular reactivity and stroke in patients with CADASIL. We retrospectively recruited 14 patients with CADASIL, eight of whom had symptomatic stroke. They underwent quantitative single-photon emission computed tomography using an autoradiographic method at rest and after acetazolamide (ACZ) administration. Regional cerebral blood flow (rCBF) in the cerebral cortex, lenticular nucleus, thalamus, and cerebellum was measured. We compared the rCBF parameters between patients with and without stroke. The baseline characteristics and magnetic resonance imaging findings were similar between the two groups, except for a higher frequency of pyramidal tract sign (75% vs. 0%) and a larger number of old lacunes (15.4 ± 8.8 vs. 2.2 ± 1.8) in the patients with stroke. Of the rCBF parameters measured, significantly lower flow (mL/100 g/min) was observed in ACZ-rCBF in the thalamus (35.6 ± 9.4 vs. 51.1 ± 7.6, Cerebrovasoreactivity in the thalamus was significantly associated with stroke in patients with CADASIL.
Sections du résumé
Background
UNASSIGNED
Impaired cerebrovasoreactivity is thought to play an important role in the pathophysiology of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). We aimed to clarify the association between cerebrovascular reactivity and stroke in patients with CADASIL.
Methods
UNASSIGNED
We retrospectively recruited 14 patients with CADASIL, eight of whom had symptomatic stroke. They underwent quantitative single-photon emission computed tomography using an autoradiographic method at rest and after acetazolamide (ACZ) administration. Regional cerebral blood flow (rCBF) in the cerebral cortex, lenticular nucleus, thalamus, and cerebellum was measured. We compared the rCBF parameters between patients with and without stroke.
Results
UNASSIGNED
The baseline characteristics and magnetic resonance imaging findings were similar between the two groups, except for a higher frequency of pyramidal tract sign (75% vs. 0%) and a larger number of old lacunes (15.4 ± 8.8 vs. 2.2 ± 1.8) in the patients with stroke. Of the rCBF parameters measured, significantly lower flow (mL/100 g/min) was observed in ACZ-rCBF in the thalamus (35.6 ± 9.4 vs. 51.1 ± 7.6,
Conclusion
UNASSIGNED
Cerebrovasoreactivity in the thalamus was significantly associated with stroke in patients with CADASIL.
Identifiants
pubmed: 36698906
doi: 10.3389/fneur.2022.1087220
pmc: PMC9868304
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1087220Informations de copyright
Copyright © 2023 Mukai, Hamano, Mizuta, Yokota, Watanabe-Hosomi, Matsuura, Koizumi, Matsuura, Ohara, Matsushima, Teramukai, Yamada and Mizuno.
Déclaration de conflit d'intérêts
IY reports grants from KAKENHI, AMED, and Health, Labor and Welfare Policy Research Grants, a research fund from Nihon Medi-Physics, and speaker fees from Chugai Pharmaceutical Co, AstraZeneca plt, Japan Tobacco Pharmaceutical Division, and Nippon Shinyaku Co., outside the submitted work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Cereb Blood Flow Metab. 2003 May;23(5):599-604
pubmed: 12771575
Neurology. 1998 Aug;51(2):452-7
pubmed: 9710018
J Cereb Blood Flow Metab. 2018 Jun;38(6):1085-1095
pubmed: 28537106
Lancet Neurol. 2009 Jul;8(7):643-53
pubmed: 19539236
Stroke. 2001 Jan;32(1):17-21
pubmed: 11136908
Bioessays. 2011 Jan;33(1):73-80
pubmed: 20967782
J Nucl Med. 1994 Dec;35(12):2019-30
pubmed: 7989987
Neuroradiology. 2013 Feb;55(3):283-90
pubmed: 23097052
Neurology. 1998 Jun;50(6):1715-21
pubmed: 9633716
Cerebrovasc Dis. 2012;33(2):128-34
pubmed: 22179564
Stroke. 2004 May;35(5):1063-7
pubmed: 15017012
Neurology. 2004 Mar 9;62(5):702-7
pubmed: 15007117
Stroke. 2000 Aug;31(8):1904-12
pubmed: 10926955
Eur J Nucl Med Mol Imaging. 2002 Mar;29(3):331-41
pubmed: 12002707
Eur J Neurol. 2020 Aug;27(8):1588-1595
pubmed: 32348626
J Nucl Med. 2003 Jun;44(6):862-9
pubmed: 12791811
Front Psychiatry. 2019 Jan 14;9:741
pubmed: 30692942
AJNR Am J Neuroradiol. 2009 Jun;30(6):1244-7
pubmed: 19270103
Stroke. 2001 Sep;32(9):2049-54
pubmed: 11546896